Printer Friendly

ST. JUDE MEDICAL DIVESTING BIOLOGICAL GRAFT BUSINESS

 ST. JUDE MEDICAL DIVESTING BIOLOGICAL GRAFT BUSINESS
 ST. PAUL, Minn., May 13 /PRNewswire/ -- St. Jude Medical, Inc.


(NASDAQ-NMS: STJM), announced today that it will be divesting its biological graft business. The graft business, which was initiated in 1984, generated sales of approximately $1.3 million in 1991.
 Larry Lehmkuhl, president and chief executive officer, said, "Although the BioPolyMeric Graft has continued to gain vascular surgeon acceptance, it has not done so at a rate that has allowed us to realize an acceptable level of return on our investment. In addition, the Food and Drug Administration's recent promulgations concerning the need to track each patient receiving a graft which is shipped after May 28, 1992, will result in significant additional costs associated with selling this product. Accordingly, we will be looking at ways to divest the business. Divesting the biological graft will not have a material effect on the company's financial statements."
 St. Jude Medical, Inc. a multinational manufacturer and marketer of the world's most preferred mechanical heart valve with over 400,000 implantations since 1977, serves physicians worldwide with the highest quality products for cardiovascular and vascular care.
 -0- 5/13/92
 /CONTACT: Steve Schuster, 612-481-7773 or Steve Wilson, 612-481-7542, both of St. Jude Medical/
 (STJM) CO: St. Jude Medical, Inc. ST: Minnesota IN: MTC SU:


KH -- MN007 -- 9561 05/13/92 10:11 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1992
Words:225
Previous Article:FINALISTS ANNOUNCED FOR 1992 NCR BOOK AWARD; MOST VALUABLE SINGLE BOOK PRIZE IN UNITED KINGDOM
Next Article:EMONS HOLDINGS REPORTS THIRD QUARTER RESULTS AND REACHES AGREEMENT IN PRINCIPLE TO MODIFY BUSINESS AND FINANCING TERMS OF RAIL SUBSIDIARY
Topics:


Related Articles
ST. JUDE MEDICAL SIGNS JOINT VENTURE AGREEMENT WITH HANCOCK-JAFFE LABORATORIES
BIO-VASCULAR NAMES SCHANKERELI DIRECTOR OF RESEARCH AND DEVELOPMENT
TELIOS SIGNS AGREEMENT WITH ST. JUDE MEDICAL INC. FOR BIOCOMPATIBLE COATING
BIO-VASCULAR NAMES KEMAL SHANKERELI VICE PRESIDENT OF RESEARCH AND DEVELOPMENT
ST. JUDE MEDICAL ANNOUNCES FDA APPROVAL OF COLLAGEN-IMPREGNATED AORTIC VALVED GRAFT
Sulzer Medica Sales in 1998 10% Over Previous Year.
St. Jude Medical to Expand Cardiac Surgery Business by Acquiring Vascular Science, Inc., a Developer of New Devices to Treat Coronary Artery Disease.
St. Jude Medical Completes Acquisition of Vascular Science, Inc., a Developer of New Devices to Treat Coronary Artery Disease.
CardioTech International, Inc. Announces the Appointment of a Director for the Middle East and Africa Region.
SYMMETRY AORTIC CONNECTOR USED IN MORE THAN 25,000 IMPLANTS.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters